The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The Phase II TaZa CLL study of tafasitamab plus zanubrutinib in newly diagnosed CLL
In this video, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses the ongoing Phase II TaZa CLL study (NCT05718869) combining tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia (CLL). Prof. Danilov notes that this trial has completed enrollment and has demonstrated promising early results. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
